2012
Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE).
Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). The Journal Of Clinical Psychiatry 2012, 73: 526-32. PMID: 22579152, PMCID: PMC3786588, DOI: 10.4088/jcp.11m07162.Peer-Reviewed Original ResearchConceptsClinical Global Impression ScalePANSS scoresClinical Antipsychotic TrialsImportant difference estimatesNegative Syndrome ScaleAntipsychotic TrialsSyndrome ScaleLong-term effectiveness trialsIntervention Effectiveness (CATIE) schizophrenia trialShort-term efficacy trialsGlobal Impression ScaleBaseline PANSS scoresLower baseline scoresClinical workIllness scoresMulticenter trialCGI scoresCGI severityImpression ScaleSchizophrenia trialsEffectiveness trialPatient ratingsEfficacy trialsImportant differencesBaseline scores
2008
A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder
Garakani A, Martinez JM, Marcus S, Weaver J, Rickels K, Fava M, Hirschowitz J. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. International Clinical Psychopharmacology 2008, 23: 269-275. PMID: 18703936, DOI: 10.1097/yic.0b013e328301a74c.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating Scale scoreMajor depressive disorderDepression Rating Scale scoresHamilton Anxiety ScaleRating Scale scoresPlacebo groupDepressive disorderScale scoreCGI improvement scoreCombination of quetiapinePlacebo-controlled trialClinical global improvementWeeks of treatmentOnset of actionMixed effects linear regressionQuetiapine augmentationAnxiety ScaleFluoxetine groupFluoxetine treatmentCGI scoresImproved sleepMixed effects regressionInsomnia scoresQuetiapineFluoxetine
1999
Limited Efficacy of Ketoconazole in Treatment-Refractory Major Depression
Malison R, Anand A, Pelton G, Kirwin P, Carpenter L, McDougle C, Heninger G, Price L. Limited Efficacy of Ketoconazole in Treatment-Refractory Major Depression. Journal Of Clinical Psychopharmacology 1999, 19: 466-470. PMID: 10505589, DOI: 10.1097/00004714-199910000-00011.Peer-Reviewed Original ResearchConceptsTreatment-refractory major depressionClinical Global Impression ScaleBeck Depression InventoryMajor depressionLimited efficacyTreatment-refractory major depressive disorderPlacebo-controlled trialGlobal Impression ScaleEfficacy of ketoconazoleHamilton Rating ScaleMajor depressive disorderAssessment of moodCGI scoresImpression ScaleDepressive disorderPatientsDepression InventoryRating ScaleKetoconazolePlaceboDepressionEfficacySignificant reductionTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply